The Promise and Challenge of GLP-1 Medications: Ensuring ROI in Obesity Care
Pricy GLP-1 medications are here to stay — let's focus on turning their potential into lasting, meaningful impact.
Pricy GLP-1 medications are here to stay — let's focus on turning their potential into lasting, meaningful impact.
Nutrition isn’t a supplement — it’s foundational to metabolic health. It’s time we integrate more ‘Food as Medicine’ initiatives alongside the GLP-1 therapies that are gaining traction.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
As multi-billion investment continues to pour into the R&D of future obesity medications, the need for evidence generation of health benefits beyond short-term weight loss will be critical to the decision-making of healthcare providers and payers.
With so many now seeking GLP-1 treatment, we must find ways to help providers care for more patients. Technology is the key to unlocking this capacity.
Employers are in a unique position to drive change in obesity care, but face several challenges. Experts shared numerous strategies employers can implement.
Ilant Health extended its seed round from $3 million to $5.5 million. The company garnered interest from LifeX Ventures, Celtic House Asia Partners and Cornucopian Capital.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
In this episode, we’re joined by Millicent Gorham, CEO of the Alliance for Women’s Health and Prevention (AWHP). AWHP recently launched the EveryBODY Covered campaign, which is advocating for comprehensive coverage of obesity care. Gorham discusses the current state of obesity treatment for women and her goals for the campaign.